Texto completo
|
Autor(es): |
Gomes, Luciana Rodrigues
[1, 2]
;
Reily Rocha, Clarissa Ribeiro
[2, 3]
;
Martins, Davi Jardim
[2]
;
Petisco Fiore, Ana Paula Zen
[4]
;
Kinker, Gabriela Sarti
[5]
;
Bruni-Cardoso, Alexandre
[4]
;
Martins Menck, Carlos Frederico
[2]
Número total de Autores: 7
|
Afiliação do(s) autor(es): | [1] Inst Butantan, Lab Especial Ciclo Celular, Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, Sao Paulo, SP - Brazil
[3] Univ Fed Sao Paulo, Escola Paulista Med, Dept Oncol Clin & Expt, Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, SP - Brazil
[5] Univ Sao Paulo, Inst Biol, Dept Fisiol, Sao Paulo, SP - Brazil
Número total de Afiliações: 5
|
Tipo de documento: |
Artigo Científico
|
Fonte: |
CELL DEATH & DISEASE;
v. 10,
JUN 12 2019.
|
Citações Web of Science: |
4
|
Resumo |
Tissue architecture and cell-extracellular matrix (cell-ECM) interaction determine the organ specificity; however, the influences of these factors on anticancer drugs preclinical studies are highly neglected. For considering such aspects, three-dimensional (3D) cell culture models are relevant tools for accurate analysis of cellular responses to chemotherapy. Here we compared the MCF-7 breast cancer cells responses to cisplatin in traditional two-dimensional (2D) and in 3D-reconstituted basement membrane (3D-rBM) cell culture models. The results showed a substantial increase of cisplatin resistance mediated by 3D microenvironment. This phenotype was independent of p53 status and autophagy activity and was also observed for other cellular models, including lung cancer cells. Such strong decrease on cellular sensitivity was not due to differences on drug-induced DNA damage, since similar levels of gamma-H2AX and cisplatin-DNA adducts were detected under both conditions. However, the processing of these cisplatin-induced DNA lesions was very different in 2D and 3D cultures. Unlike cells in monolayer, cisplatin-induced DNA damage is persistent in 3D-cultured cells, which, consequently, led to high senescence induction. Moreover, only 3D-cultured cells were able to progress through S cell cycle phase, with unaffected replication fork progression, due to the upregulation of translesion (TLS) DNA polymerase expression and activation of the ATR-Chk1 pathway. Co-treatment with VE-821, a pharmacological inhibitor of ATR, blocked the 3D-mediated changes on cisplatin response, including low sensitivity and high TLS capacity. In addition, ATR inhibition also reverted induction of REV3L by cisplatin treatment. By using REV3L-deficient cells, we showed that this TLS DNA polymerase is essential for the cisplatin sensitization effect mediated by VE-821. Altogether, our results demonstrate that 3D-cell architecture-associated resistance to cisplatin is due to an efficient induction of REV3L and TLS, dependent of ATR. Thus co-treatment with ATR inhibitors might be a promising strategy for enhancement of cisplatin treatment efficiency in breast cancer patients. (AU) |
|
Processo FAPESP: |
14/15982-6 - Consequências de deficiências de reparo de lesões no genoma
|
Beneficiário: | Carlos Frederico Martins Menck |
Linha de fomento: |
Auxílio à Pesquisa - Temático
|
|
|
Processo FAPESP: |
11/50856-3 - Papel do microambiente celular nos mecanismos moleculares de resistência a quimioterápicos em modelo de carcinoma mamário humano
|
Beneficiário: | Luciana Rodrigues Gomes |
Linha de fomento: |
Bolsas no Brasil - Pós-Doutorado
|
|
|
Processo FAPESP: |
14/10492-0 - Hippo-YAP como uma via de convergência dos sinais bioquímicos e mecânicos provenientes da matriz extracelular durante a morfogênese da glândula mamária e a progressão do câncer de mama
|
Beneficiário: | Alexandre Bruni Cardoso |
Linha de fomento: |
Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
|
|
|
Processo FAPESP: |
14/25832-1 - A via Hippo-YAP como mediadora de sinais bioquímicos da matriz extracelular em células epiteliais não-malignas e malignas da glândula mamária
|
Beneficiário: | Ana Paula Zen Petisco Fiore |
Linha de fomento: |
Bolsas no Brasil - Pós-Doutorado
|
|